CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 41 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Nebivolol 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02710071
NCT02710071Phase 4Completed
CompareCT.gov

A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide

University of California, San Diego·interventional·Posted Mar 16, 2016·Updated Oct 19, 2020

In Brief

A Phase 4 clinical trial evaluating Nebivolol and Hydrochlorothiazide for Hypertension. Completed, enrolled 41 participants.

Detailed Summary

Patients who have obstructive sleep apnea (OSA) frequently stop breathing while they sleep. They often develop high blood pressure. We are not sure what drug is best to treat the high blood pressure. This study will give the patients nebivolol or hydrochlorothiazide (HCTZ) for 6 weeks after 2 weeks of placebo. The blood pressure response will be evaluated by 24 hour monitoring.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 16, 2016
Enrollment StartJan 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.3 years ago

Interventions

Nebivololdrug

Nebivolol 5mg then nebivolol 10 mg

Hydrochlorothiazidedrug

Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg